Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, B-Cell, Marginal Zone 4Waldenstrom Macroglobulinemia 3Leukemia 3Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Leukemia, B-Cell 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 176Rituximab 164fludarabine phosphate 97Peripheral Blood Stem Cell Transplantation 95Filgrastim 73Etoposide 67Radiotherapy 63Mycophenolic Acid 62Whole-Body Irradiation 58Tacrolimus 49Melphalan 49Cyclosporine 49Busulfan 47Lenalidomide 45Antilymphocyte Serum 39Vincristine 37Prednisone 37Cytarabine 37fludarabine 35Methotrexate 33Carmustine 32obinutuzumab 31Doxorubicin 30Bendamustine Hydrochloride 30Methylprednisolone 27ibritumomab tiuxetan 25Cord Blood Stem Cell Transplantation 25sargramostim 24Bortezomib 24Granulocyte Colony-Stimulating Factor 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Follicular × pirtobrutinib × Clear all
NCT06948786 2026-06-04

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

University of Washington

Phase 2 Recruiting
22 enrolled
Lymphoid

Lymphoma, Follicular

NCT05990465 2026-02-23

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Medical College of Wisconsin

Phase 1 Recruiting
12 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡